Kewaunee Scientific clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Kewaunee Scientific Corp
KEQU · NASDAQ · USD · Market cap $95M · 1,239 employees
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products.
Not yet scoredPrice as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price35.70 USD at the 13 Nov 2026 close
- Fair value17.85. Our model only; no analyst estimate to cross-check.
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenNot yet scored
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $17.85 to $28.08, base estimate $17.85 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Kewaunee Scientific Corp holds its Markup at $35.70. Elevated stress, defensive posture warranted, held for 146 days.
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 146 days |
| Price at the screen | $35.70 |
| Valuation | 11.88 trailing · 15.18 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.76 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 16.93% | Below 33% | Interest-bearing debt is just 16.9% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 38.52% | Below 49% | Money owed to the company is 38.5% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Kewaunee Scientific clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Kewaunee Scientific clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 17%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our model only; no analyst estimate to cross-check.
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $17.85 fair value estimate, none competitive moat.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 100.0% above the base estimate.
Where our models see it going: fair-value estimate $17.85, with a range of $17.85 to $28.08, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 15.2x forward earnings, the price already runs ahead of the business. It trades 100% above our $17.85 fair value, so you would be buying at a premium, not a discount. The none moat is real, but quality alone does not make an expensive price cheap.
| Forward P/E | 15.2xreasonably valued |
| Trailing P/E | 11.9xreasonably valued |
| EPS, trailing | 2.76 |
| EPS, forward | 2.16 |
| Revenue growth | -6.7%revenue is shrinking |
| Profit margin | 3.0%barely profitable |
| Return on equity | 12.5%a solid return on shareholder capital |
| FCF yield | 9.73% |
| Debt to equity | 0.72moderate, manageable leverage |
| Current ratio | 2.20comfortably covers its short-term bills |
| Beta | 0.76steadier than the market |
| Short interest, float | 0.02% |
| 52-week range | 32.00 - 46.57 |
| Moat | NONE |
| Market cap | $95M |
| Employees | 1,239 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeKEQU trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 28%. Since the last review it dropped out of the Titan Ethical 500.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Kewaunee Q1 Earnings Fall Y/Y Despite International Strength Zacks · 10 Sep 2026
- Kewaunee Q1 Earnings Fall Y/Y Despite International Strength Yahoo Finance · 10 Sep 2026
- Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 Yahoo Finance · 9 Sep 2026
- Kewaunee Scientific Posts Record $282M Revenue, Maps Fiscal 2027 Growth Investments MarketBeat · 29 Aug 2026
- Kewaunee Scientific Posts Record $282M Revenue, Maps Fiscal 2027 Growth Investments Yahoo Finance · 29 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $36.67 | -3.2% | · | $968 | -3.2% |
| 2 months | $34.93 | +1.6% | · | $1,016 | +1.6% |
| 3 months | $35.62 | -0.3% | · | $997 | -0.3% |
| 6 months | $38.26 | -7.2% | · | $928 | -7.2% |
| 1 year | $39.49 | -10.1% | · | $899 | -10.1% |
| 2 years | $40.95 | -13.3% | · | $867 | -13.3% |
| 3 years | $16.00 | +121.9% | · | $2,219 | +121.9% |
| 5 years | $11.75 | +202.1% | · | $3,021 | +202.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever KEQU does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.